Lipoprotein(a): Measurement and Clinical Implications

Definition and structure

Lipoprotein(a), abbreviated Lp(a), is an LDL-like circulating lipoprotein particle. It contains one molecule of apolipoprotein B covalently attached to apolipoprotein(a). The length of apolipoprotein(a) varies because of genetically determined differences in the number of kringle-IV type 2 repeats.

Lp(a) concentration is predominantly genetically determined, with heritability estimated at approximately 85% to more than 90%. Levels vary among ethnic groups and generally remain relatively stable throughout life. Lp(a) is elevated in approximately one in five individuals.

Pathophysiology

Lp(a) is associated with several interrelated pathological processes:

• accelerated atherogenesis;

• vascular inflammation;

• progression of calcific aortic stenosis;

• enhancement of a prothrombotic state.

Its atherogenic and inflammatory effects may be mediated partly by oxidized phospholipids carried on the particle. Genetic and Mendelian-randomization studies support a causal relationship between Lp(a)-associated genetic variants and coronary artery disease. Associations have also been extended to peripheral arterial disease, ischaemic stroke, abdominal aortic aneurysm, and calcific aortic valve stenosis.

Lp(a) is not associated with venous thromboembolism in prospective epidemiological studies. Its biological effects appear to differ from those of LDL, and elevated Lp(a) may confer greater risk per particle or unit of cholesterol than LDL cholesterol.

Clinical implications

High Lp(a) is independently associated with first and recurrent atherosclerotic cardiovascular disease events. The strongest observed associations are with myocardial infarction and aortic valve stenosis; associations are less pronounced with peripheral arterial disease and heart failure, and weakest with ischaemic stroke and cardiovascular or all-cause mortality.

Risk rises gradually from approximately 30 mg/dL (62 nmol/L) to 50 mg/dL (105 nmol/L), becomes clinically relevant above 50 mg/dL (105 nmol/L), and increases further at higher concentrations. A concentration above 50 mg/dL (≥105 nmol/L) can therefore be considered a cardiovascular risk modifier, particularly when baseline risk is moderate or near a treatment decision threshold.

Failure to account for a high Lp(a) level may lead to substantial underestimation of cardiovascular risk. Conversely, Lp(a) measurement provides limited additional reclassification beyond currently recommended global risk scores, and its interpretation should remain integrated with the overall risk profile.

Measurement

Who should be tested?

Current recommendations support measuring Lp(a) at least once in every adult’s lifetime. Testing is particularly relevant in:

• individuals with premature atherosclerotic cardiovascular disease;

• patients with familial hypercholesterolaemia or very high LDL cholesterol;

• people with a family history of premature cardiovascular disease;

• those with a family history of high Lp(a);

• individuals with cardiovascular disease that is not explained by major conventional risk factors;

• patients at moderate risk or close to a treatment threshold, when risk refinement may influence management.

A single measurement is generally sufficient because Lp(a) is genetically determined and does not fluctuate substantially over the lifetime. A repeat test may be reasonable after menopause when a premenopausal value was borderline, because levels may increase during this period.

Cascade testing of parents, siblings, and children can identify relatives with high Lp(a) and increased risk of premature cardiovascular disease.

Units and assay considerations

Lp(a) may be reported in mass units as mg/dL or in molar units as nmol/L. Molar reporting is preferred. Direct conversion between mg/dL and nmol/L is unreliable because particle mass varies with apolipoprotein(a) structure and kringle-IV repeat number.

Assays show substantial variability, partly because apolipoprotein(a) isoform size can lead to underestimation or overestimation. Results should therefore be interpreted with awareness of the assay used and the reporting units.

Laboratory assessment in the cardiovascular patient

In patients with established or suspected coronary artery disease, assessment should include:

• total cholesterol;

• LDL cholesterol;

• HDL cholesterol;

• triglycerides;

• serum creatinine or cystatin C with estimation of glomerular filtration rate;

• glycated haemoglobin.

A fasting lipid profile is required when severe dyslipidaemia or hypertriglyceridaemia is being characterized or followed, but is not necessary in all other circumstances.

Apolipoprotein B may provide additional prognostic information after LDL cholesterol has reached its therapeutic target, although routine measurement lacks consensus. Non-HDL cholesterol, particularly when triglycerides exceed 200 mg/dL, may capture much of the clinically relevant information concerning other atherogenic particles.

Risk interpretation and clinical evaluation

Lp(a) should be viewed as a risk-enhancing or risk-modifying factor rather than as an isolated diagnostic entity. The clinical significance of a measured concentration depends on:

• the absolute Lp(a) level;

• age and sex;

• conventional cardiovascular risk factors;

• personal history of atherosclerotic disease;

• family history;

• LDL cholesterol and other atherogenic lipid measures;

• presence of chronic kidney disease, diabetes, or other conditions associated with vascular risk.

A high Lp(a) level is especially important in younger patients with premature disease and no clear explanation from conventional risk factors. It can also support more intensive preventive treatment when the decision to initiate or intensify lipid-lowering therapy is otherwise uncertain.

Treatment and management

General principles

No completed clinical-outcomes evidence has yet established that pharmacologically lowering Lp(a) reduces atherosclerotic cardiovascular events or slows aortic valve stenosis. The magnitude of Lp(a) reduction required to produce clinical benefit is also unknown.

In the absence of an established specific therapy, management should focus on rigorous control of modifiable cardiovascular risk factors. More intensive LDL-cholesterol lowering is reasonable, taking into account both absolute cardiovascular risk and the Lp(a) concentration.

Patients with sufficiently high overall risk should be encouraged to initiate or continue high-intensity statin therapy. Decisions should not be based on an isolated attempt to alter the Lp(a) concentration, but on the total cardiovascular risk profile.

Lipid-lowering therapies

RNA-based therapies inhibit hepatic production of apolipoprotein(a). Their potential is substantial, but assessment of adverse effects remains essential. Lower Lp(a) levels have been associated with a modestly increased risk of diabetes in genetic analyses, emphasizing the need for careful evaluation of the net clinical effect.

LDL-cholesterol management

Until specific Lp(a)-directed treatments with proven outcome benefit are available, intensified LDL-cholesterol lowering is the principal pharmacological response to elevated Lp(a), when justified by overall risk. Evidence-based options beyond statins include:

• ezetimibe;

• PCSK9 inhibitors;

• bempedoic acid.

Inclisiran is also identified as an adjunctive LDL-lowering therapy in patients with residual lipid risk. The choice of treatment should be guided by cardiovascular risk, lipid concentrations, treatment thresholds, and the broader clinical context rather than by Lp(a) alone.

Guideline recommendations

The principal recommendations are:

• Measure Lp(a) once during adulthood, preferably using an assay reporting nmol/L.

• Give particular priority to testing in premature atherosclerotic cardiovascular disease, familial hypercholesterolaemia, strong family histories, unexplained cardiovascular disease, and individuals near treatment decision thresholds.

• Consider Lp(a) above 50 mg/dL (≥105 nmol/L) as a cardiovascular risk modifier.

• Use cascade testing to identify affected first-degree relatives when a high Lp(a) concentration is found.

• Do not use niacin specifically to lower Lp(a), because clinical benefit has not been demonstrated.

• In patients with sufficiently high overall risk, reinforce adherence to high-intensity statin therapy despite a high Lp(a) concentration.

• In the absence of proven Lp(a)-specific outcome therapy, intensify management of LDL cholesterol and other modifiable risk factors.

• Recognize that targeted antisense oligonucleotide and small interfering RNA therapies remain investigational pending cardiovascular-outcome trials.

Biomarkers and related laboratory testing

Lp(a) is a biomarker that may reflect a pathogenic lipid fraction rather than merely mark risk. However, its incremental contribution to risk prediction beyond conventional risk factors and established risk scores is limited.

Other biomarkers have not established a routine role in Lp(a)-based risk assessment. C-reactive protein has limited additional predictive value beyond traditional risk factors, although high-sensitivity C-reactive protein may identify residual inflammatory risk in patients receiving contemporary lipid-lowering therapy. Natriuretic peptides and high-sensitivity cardiac troponin may indicate early cardiac damage, but further work is required before cardiac biomarkers can be routinely incorporated into risk assessment for suspected chronic coronary syndrome.

General screening for homocysteine is not recommended: the association between elevated homocysteine and atherogenesis is modest, and trials of homocysteine-lowering interventions have not demonstrated clinical benefit.

Prognosis and follow-up

A high Lp(a) concentration is associated with increased lifetime risk of myocardial infarction, stroke, atherosclerotic cardiovascular disease recurrence, and calcific aortic valve stenosis. Risk rises across the concentration spectrum rather than appearing only at a single threshold.

Because Lp(a) is relatively stable over time, repeated measurement is not routinely required. Follow-up should instead focus on:

• reassessment of global cardiovascular risk;

• monitoring and treatment of LDL cholesterol and other atherogenic lipids;

• surveillance of renal function and glycaemic status where clinically appropriate;

• reinforcement of lifestyle and pharmacological risk-factor management;

• family-based testing when a markedly elevated value or relevant family history is present.

The long-term prognostic benefit of lowering Lp(a) remains unresolved. Ongoing randomized trials of antisense oligonucleotide, small interfering RNA, and other Lp(a)-targeted therapies will determine whether biochemical reduction translates into fewer cardiovascular events or less progression of aortic valve stenosis.